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Background:  One pillar of heart failure (HF) is the depletion of the calcium (Ca2+) sensor protein S100A1 driving progressive deterioration of 
cardiac performance and transition to failure. Repairing this molecular defect by genetically-targeted S100A1 replacement in preclinical studies 
reversed the disease by restoring cardiomyocyte Ca2+ handling.
Methods:  This study sought to determine significance of S100A1 genetically-targeted therapy in human failing myocardium focusing on the key 
pathological features emanating from contractile dysfunction and negative force-frequency response (FFR), blunted contractile reserve, susceptibility 
to arrhythmogenic Ca2+ leakage and impaired energy homeomostasis in failing ventricular cardiomyocytes.
Results:  S100A1 genetically-targeted therapy of isolated human failing cardiomyocytes (HFCMs) employing the human S100A1 cDNA both 
reversed contractile dysfunction and negative FFR due to normalized S100A1 protein expression. Therapeutic effects of restored S100A1 expression 
extended into enhanced contractile reserve of HFCMs under `-adrenergic receptor (`-AR) stimulation occuring independent of cAMP-dependent 
(PKA) and calmodulin-dependent (CaMKII) kinase activity. S100A1 gene replacement reversed underlying Ca2+ handling abnormalities in HFCMs 
basally and under `-AR stimulation comprising of enhanced SR Ca2+ load and intracellular Ca2+ transients, decreased diastolic Ca2+ overload and 
susceptibility to arrhythmogenic SR Ca2+ leak. As a result of normalized diastolic Ca2+ handling, S100A1 improved compromised mitochondrial 
function illustrated by normalized phosphocreatine (CP)/Adenosine-tri-phosphate (ATP) ratio, predictive of superior clinical outcome.
Conclusions:  Our results demonstrate that S100A1 gene replacement exerts a favorable therapeutic profile reversing key pathological features 
characteristic of human failing myocardium and pave the way for S100A1 genetically-targeted therapy towards clinical application in human HF.
